Piper Sandler Maintains Overweight on Apyx Medical, Raises Price Target to $4.5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on Apyx Medical (NASDAQ:APYX) and raises the price target from $4 to $4.5.
August 11, 2023 | 4:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler's raised price target for Apyx Medical suggests a positive outlook for the company's stock.
The raised price target by Piper Sandler indicates their positive outlook on Apyx Medical's stock. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100